28 C
March 1, 2024
The Hona News

Controlling respiratory syncytial virus: Real-life data from Luxembourg

Respiratory syncytial virus (RSV) is one of the main reasons leading to hospitalization among young children worldwide and each year, an estimated 101,000 children below the age of 5 years die due to RSV infections. Since the end of 2022, the use of a long-acting monoclonal antibody (nirsevimab) in infants as means of passive immunization against RSV has been allowed in the European Union and European Economic Area (EU/EEA). However, only a few countries in the EU/EEA started using nirsevimab prior to the RSV season 2023/24.

Source link

Related posts

Is it broken? A strain or sprain? How to spot a serious injury now school and sport are back


New research challenges notion that post-meal insulin surge is a bad thing


Up to three daily servings of kimchi may lower men's obesity risk


Leave a Comment